Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | MRGPRX1 | Q96LB2 | 4/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851124 | 0.82 | PGR (0.54) | PGRCACNA1HCACNA1BSLC16A3SLC22A12 | |
| SCHEMBL850454 | 0.82 | MRGPRX1 (0.63) | PGRBRAFMRGPRX1 | |
| SCHEMBL851411 | 0.78 | MRGPRX1 (0.51) | PGRBRAFSLC16A3MRGPRX1 | |
| SCHEMBL851450 | 0.75 | SLC22A12 (0.54) | PGRCACNA1HCACNA1BMRGPRX1SLC22A12 | |
| SCHEMBL27803879 | 0.71 | SLC6A4 (0.51) | — | |
| SCHEMBL5955965 | 0.71 | PGR (0.56) | PGRACLY | |
| SCHEMBL10337745 | 0.69 | PTGS1 (0.61) | PGRCACNA1HCACNA1BSLC22A12ACLY | |
| SCHEMBL7571206 | 0.68 | RECQL (0.69) | SLC22A12ACLYPTGES2 | |
| SCHEMBL5955962 | 0.68 | USP2 (0.57) | PGRSLC16A3MRGPRX1BCL2L1MCL1 | |
| SCHEMBL8432578 | 0.68 | SLC6A4 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | PGR 354/4885FNTA 2355/4885FNTB 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.